August 1, 1996The Journal of Infectious DiseasesOpen Access

Safety, Immunogenicity, and Protective Efficacy of One and Three Doses of the Tetravalent Rhesus Rotavirus Vaccine in Infants in Lima, Peru

View Full Paper

Ask AI

Bookmark

Why the study?

Does the RRV-TV vaccine improve immunogenicity and prevent rotavirus diarrhea in infants?

Population

Infants in Lima, Peru

Comparison

Oral rhesus-human rotavirus tetravalent vaccine… vs Placebo administered at 2, 3, and 4 months of age

Design

RCT

Authors

CLClaudio F. LanataInstituto de Investigación Nutricional KMK MidthunUnited States Food and Drug Administration RBRobert E. BlackGlobal Forum for Health Research

Discussion

Member takes

Implication

Supports RRV-TV for reducing severe rotavirus diarrhea in infants; confirms immunogenicity but leaves open full protection against all episodes.

Structured PICO

Does the RRV-TV vaccine improve immunogenicity and prevent rotavirus diarrhea in infants?

Population

Infants in Lima, Peru

Intervention

Oral rhesus-human rotavirus tetravalent (RRV-TV) vaccine (10(4) pfu), administered as either one dose (at 2 months followed by placebo at 3 and 4 months) or three doses (at 2, 3, and 4 months of age)

Comparator

Placebo administered at 2, 3, and 4 months of age

Outcome

Rotavirus-specific IgA responses, neutralizing antibody response, and protection against rotavirus diarrheahard clinical

The RRV-TV vaccine induced significant immune responses and provided partial protection against severe rotavirus diarrhea, though it failed to significantly protect against all rotavirus diarrhea episodes.

Cite This Study

Lanata et al. (1996) studied this question.

synapsesocial.com/papers/6a700a9178a11c550e09d586 https://doi.org/10.1093/infdis/174.2.268

View Full Paper

Ask AI

Bookmark

Implication

Supports RRV-TV for reducing severe rotavirus diarrhea in infants; confirms immunogenicity but leaves open full protection against all episodes.

Safety, Immunogenicity, and Protective Efficacy of One and Three Doses of the Tetravalent Rhesus Rotavirus Vaccine in Infants in Lima, Peru

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Safety, Immunogenicity, and Protective Efficacy of One and Three Doses of the Tetravalent Rhesus Rotavirus Vaccine in Infants in Lima, Peru

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider